138 related articles for article (PubMed ID: 2888792)
1. Esmolol-digoxin drug interaction.
Lowenthal DT; Porter RS; Achari R; Turlapaty P; Laddu AR; Matier WL
J Clin Pharmacol; 1987 Aug; 27(8):561-6. PubMed ID: 2888792
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics of esmolol in pediatric subjects with supraventricular arrhythmias.
Adamson PC; Rhodes LA; Saul JP; Dick M; Epstein MR; Moate P; Boston R; Schreiner MS
Pediatr Cardiol; 2006; 27(4):420-7. PubMed ID: 16835806
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of esmolol in children.
Wiest DB; Trippel DL; Gillette PC; Garner SS
Clin Pharmacol Ther; 1991 Jun; 49(6):618-23. PubMed ID: 1676357
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology, pharmacodynamics and interactions with esmolol.
Lowenthal DT; Porter RS; Saris SD; Bies CM; Slegowski MB; Staudacher A
Am J Cardiol; 1985 Oct; 56(11):14F-18F. PubMed ID: 2864843
[TBL] [Abstract][Full Text] [Related]
5. Combined use of esmolol and digoxin in the acute treatment of atrial fibrillation or flutter.
Shettigar UR; Toole JG; Appunn DO
Am Heart J; 1993 Aug; 126(2):368-74. PubMed ID: 8101692
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of esmolol and ASL-8123 in renal failure.
Flaherty JF; Wong B; La Follette G; Warnock DG; Hulse JD; Gambertoglio JG
Clin Pharmacol Ther; 1989 Mar; 45(3):321-7. PubMed ID: 2563962
[TBL] [Abstract][Full Text] [Related]
7. Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group.
Krumpl G; Ulc I; Trebs M; Kadlecová P; Hodisch J
Eur J Clin Pharmacol; 2017 Apr; 73(4):417-428. PubMed ID: 28091703
[TBL] [Abstract][Full Text] [Related]
8. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias.
Gray RJ; Bateman TM; Czer LS; Conklin CM; Matloff JM
J Am Coll Cardiol; 1985 Jun; 5(6):1451-6. PubMed ID: 2860148
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Pharmacodynamics of Low-, Intermediate-, and High-Dose Landiolol and Esmolol During Long-Term Infusion in Healthy Whites.
Krumpl G; Ulč I; Trebs M; Kadlecová P; Hodisch J; Maurer G; Husch B
J Cardiovasc Pharmacol; 2018 Mar; 71(3):137-146. PubMed ID: 29112591
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of esmolol administered as an intravenous bolus.
Sintetos AL; Hulse J; Pritchett EL
Clin Pharmacol Ther; 1987 Jan; 41(1):112-7. PubMed ID: 2879662
[TBL] [Abstract][Full Text] [Related]
11. Effects of long-term oral carvedilol on the steady-state pharmacokinetics of oral digoxin in patients with mild to moderate hypertension.
Wermeling DP; Field CJ; Smith DA; Chandler MH; Clifton GD; Boyle DA
Pharmacotherapy; 1994; 14(5):600-6. PubMed ID: 7997394
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent, in children.
Cuneo BF; Zales VR; Blahunka PC; Benson DW
Pediatr Cardiol; 1994; 15(6):296-301. PubMed ID: 7838803
[TBL] [Abstract][Full Text] [Related]
13. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
Westphal K; Weinbrenner A; Giessmann T; Stuhr M; Franke G; Zschiesche M; Oertel R; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Jul; 68(1):6-12. PubMed ID: 10945310
[TBL] [Abstract][Full Text] [Related]
14. Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.
Wiest D
Clin Pharmacokinet; 1995 Mar; 28(3):190-202. PubMed ID: 7758250
[TBL] [Abstract][Full Text] [Related]
15. Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties.
Volz-Zang C; Eckrich B; Jahn P; Schneidrowski B; Schulte B; Palm D
Eur J Clin Pharmacol; 1994; 46(5):399-404. PubMed ID: 7957532
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics and onset of action of esmolol in anesthetized dogs.
Quon CY; Gorczynski RJ
J Pharmacol Exp Ther; 1986 Jun; 237(3):912-8. PubMed ID: 2872328
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia.
Sung RJ; Blanski L; Kirshenbaum J; MacCosbe P; Turlapaty P; Laddu AR
J Clin Pharmacol; 1986 Mar; 26(S1):A15-A26. PubMed ID: 2870082
[TBL] [Abstract][Full Text] [Related]
18. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.
Angaran DM; Schultz NJ; Tschida VH
Clin Pharm; 1986 Apr; 5(4):288-303. PubMed ID: 2871961
[TBL] [Abstract][Full Text] [Related]
19. Esmolol for the management of pediatric hypertension after cardiac operations.
Wiest DB; Garner SS; Uber WE; Sade RM
J Thorac Cardiovasc Surg; 1998 Apr; 115(4):890-7. PubMed ID: 9576226
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of esmolol and fentanyl in controlling increases in heart rate and blood pressure during endotracheal intubation.
Gaubatz CL; Wehner RJ
AANA J; 1991 Feb; 59(1):91-6. PubMed ID: 1672049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
